4D-150 IVT (3E10 vg/eye) + EYLEA® (aflibercept) Injection 2 mg (0.05mL)
Phase 3Recruiting 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Neovascular Age-Related Macular Degeneration (nAMD)
Conditions
Neovascular Age-Related Macular Degeneration (nAMD)
Trial Timeline
Jul 22, 2025 → Feb 1, 2029
NCT ID
NCT07064759About 4D-150 IVT (3E10 vg/eye) + EYLEA® (aflibercept) Injection 2 mg (0.05mL)
4D-150 IVT (3E10 vg/eye) + EYLEA® (aflibercept) Injection 2 mg (0.05mL) is a phase 3 stage product being developed by 4D Molecular Therapeutics for Neovascular Age-Related Macular Degeneration (nAMD). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07064759. Target conditions include Neovascular Age-Related Macular Degeneration (nAMD).
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07064759 | Phase 3 | Recruiting |
| NCT06864988 | Phase 3 | Recruiting |
Competing Products
20 competing products in Neovascular Age-Related Macular Degeneration (nAMD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CLS-AX + Anti-VEGF | Clearside Biomedical | Phase 1/2 | 33 |
| CLS-AX + Aflibercept | Clearside Biomedical | Phase 2 | 44 |
| Eylea + ALT-L9 | Alteogen | Phase 1 | 33 |
| UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL) | Unity Biotechnology | Phase 2 | 44 |
| DS-7080a + Ranibizumab | Daiichi Sankyo | Phase 1 | 33 |
| Avacincaptad Pegol | Astellas Pharma | Phase 1 | 33 |
| Avacincaptad Pegol + Avastin + Lucentis + Eylea | Astellas Pharma | Phase 2 | 52 |
| Avacincaptad Pegol + Lucentis | Astellas Pharma | Phase 2 | 52 |
| KHK4951 + Aflibercept Injection | Kyowa Kirin | Phase 2 | 52 |
| Surabgene Lomparvovec (ABBV-RGX-314) + Ranibizumab Control | AbbVie | Phase 3 | 77 |
| Ranibizumab + Local Steroid + Topical Steroid | AbbVie | Phase 2 | 52 |
| Lucentis | Novartis | Pre-clinical | 23 |
| ranibizumab | Novartis | Phase 3 | 77 |
| Brolucizumab | Novartis | Pre-clinical | 23 |
| ranibizumab | Novartis | Approved | 85 |
| brolucizumab + ranibizumab + aflibercept | Novartis | Pre-clinical | 23 |
| Beovu | Novartis | Pre-clinical | 23 |
| Ranibizumab | Novartis | Phase 3 | 77 |
| Ranibizumab | Novartis | Approved | 85 |
| Intraviteal Ranibizumab 0.5mg | Novartis | Approved | 85 |